Tarsus Pharmaceuticals, Inc. (TARS) Tops Q4 EPS by 17c
Tweet
Share
E-mailGet Alerts TARS Hot Sheet
Join SI Premium – FREE
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q4 EPS of ($0.60), $0.17 better than the analyst estimate of ($0.77). Revenue for the quarter came in at $66.41 million versus the consensus estimate of $57.53 million.
For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA maintains underperform ratings on six BDC stocks
- loanDepot receives NYSE non-compliance notice over stock price
- Myriad Uranium completes acquisition of Rush Rare Metals
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
